ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the 2024 full-year financial outlook has been updated. Revenue is now expected to grow by 10-13% in local currencies (previously: 9-12%). The ...

On 18 April 2024, the US Food and Drug Administration (FDA) approved Roche’s Alecensa (alectinib), an oral anaplastic ...

On May 3, Alk-Abello A-S Bearer and-or registered B will release figures for Q1. 3 analysts are estimating earnings of DKK 0.977 per share compared to earnings of DKK 0.740 per share in the same ...

Alaska Air Group (ALK) closed the last trading session at $43.96, gaining 2.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...

Alecensa was shown to reduce the risk of disease recurrence or death by 76% versus chemotherapy for patients with ALK-positive non-small cell lung cancer.

Due to its increased sensitivity and capacity to identify mutations with low allele frequency, next-generation sequencing ...

Investors with an interest in Transportation - Airline stocks have likely encountered both Alaska Air Group (ALK) and Ryanair (RYAAY). But which of these two companies is the best option for those ...

The US Food and Drug Administration (FDA) has approved alectinib (Alecensa, Genentech) in the adjuvant setting following ...

Alaska Air Group (ALK) is a stock many investors are watching right now. ALK is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A. The stock holds a P/E ratio of 8.98, while its ...

Seeking more data on adjuvant alectinib in patients who have resectable ALK-positive non–small cell lung cancer (NSCLC), ...

1 Day ALK -2.43% DJIA -1.49% S&P 500 -1.57% Transportation/Logistics 0.94% ...

As Bitcoin consolidates just hours ahead of the halving, traders are hunting on-chain markets for top crypto gainers today.